Canada’s health regulator has approved Novo Nordisk’s weight loss drug Wegovy to reduce the risk of nonfatal heart attack or myocardial infarction in some adults, the Danish drugmaker said on Wednesday.
Wegovy has become the first approved treatment in Canada to address both obesity and the risk of heart-related conditions in adults with established cardiovascular disease, according to Novo.
The European Union health regulator recently backed the drug for reducing the risk of major cardiovascular events and strokes in overweight or obese adults without diabetes.
Wegovy is also approved in the U.K. and the U.S. to lower the risk of serious heart problems or strokes in overweight and obese adults.
The drug, chemically known as semaglutide, has been authorized in Canada to treat obesity since 2021.
(Reporting by Mariam Sunny in Bengaluru; Editing by Tasim Zahid)
The federal Conservatives are calling on Ottawa to designate Kata’ib Hezbollah as a terrorist entity,…
The midstream energy sector continues to demonstrate its commitment to returning capital to shareholders. Major…
HAMILTON – Folarin Orimolade and Calgary’s defence earned the Stampeders a road win Saturday afternoon.…
NewsFeedPolice said at least three people were killed several others were wounded in a shooting…
Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure On-chain data…
EDMONTON – Backup quarterback Tommy Stevens scored three touchdowns as the Saskatchewan Roughriders evened their…